CJC-1295 GHRH-R Research: GH Axis Signalling and Pituitary Cell Model Studies

CJC-1295 GHRH-R Research: GH Axis Signalling and Pituitary Cell Model Studies

CJC-1295 is a research compound studied in cell-based assay formats for its GHRH-R (class B GPCR) Gs/cAMP/PKA signalling with DAC albumin-binding modification. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.

Receptor Pharmacology and Mechanism of Action

CJC-1295 acts via GHRH-R (class B GPCR) Gs/cAMP/PKA signalling with DAC albumin-binding modification. The compound exhibits selective binding interactions at the growth hormone-releasing hormone receptor, a member of the secretin family of G-protein coupled receptors. In vitro binding studies demonstrate high affinity interactions with GHRH-R expressed in transfected cell lines.

The drug affinity complex (DAC) modification involves lysine substitution at position 2, enabling covalent albumin binding through maleimidopropionic acid linkage. This structural modification significantly alters pharmacokinetic parameters in cell culture media containing albumin, extending compound stability and prolonging receptor engagement duration in time-course assays.

Receptor Binding Characteristics

Competitive binding assays using radiolabeled GHRH demonstrate CJC-1295 binding affinity (Ki) values in the nanomolar range at recombinant GHRH receptors. Saturation binding experiments reveal reversible, specific interactions with receptor sites, displaying typical GPCR binding kinetics. Scatchard plot analysis confirms single-site binding behaviour consistent with GHRH-R selectivity.

Structure-activity relationship studies indicate critical amino acid residues for receptor recognition, particularly the N-terminal domain responsible for receptor activation. The C-terminal DAC modification does not significantly impact binding affinity but substantially influences compound-albumin interactions in serum-containing media.

Signalling Pathway Activation

cAMP-PKA Cascade Engagement

GHRH-R activation by CJC-1295 triggers Gs protein-mediated adenylyl cyclase stimulation, resulting in intracellular cAMP accumulation. Dose-response curves in CHO-K1 cells stably expressing human GHRH-R demonstrate EC50 values for cAMP production in the low nanomolar range. Time-course studies reveal sustained cAMP elevation compared to native GHRH, attributed to enhanced receptor occupancy duration.

Protein kinase A (PKA) activation occurs downstream of cAMP elevation, measured through PKA substrate phosphorylation assays. Western blot analysis shows enhanced CREB phosphorylation at Ser133, indicating successful signal transduction through the canonical GHRH-R pathway.

Transcriptional Response Mechanisms

Luciferase reporter assays utilising CRE-driven constructs demonstrate transcriptional activation following CJC-1295 treatment in GHRH-R expressing cell lines. Quantitative PCR analysis reveals upregulation of immediate early genes including c-fos and egr-1, consistent with CREB-mediated transcriptional responses.

Gene expression profiling in pituitary adenoma cell lines (GH3, GH4C1) shows dose-dependent increases in growth hormone mRNA levels, measured through real-time PCR. These transcriptional effects correlate with cAMP response element activation, confirming pathway specificity.

Cell Model Applications

Primary Pituitary Cell Cultures

Primary rat anterior pituitary cell cultures serve as physiologically relevant models for CJC-1295 mechanism studies. Dispersed pituitary cells maintain GHRH-R expression and demonstrate robust cAMP responses to compound treatment. Flow cytometry analysis reveals somatotroph-specific responses, identified through growth hormone immunostaining.

Calcium imaging studies in primary somatotrophs show secondary calcium mobilisation following PKA activation, indicating complex intracellular signalling networks. These calcium responses correlate with growth hormone secretion patterns measured through enzyme-linked immunosorbent assays.

Immortalised Cell Line Models

GH3 pituitary adenoma cells provide standardised models for receptor pharmacology studies, expressing endogenous GHRH-R at physiologically relevant levels. Concentration-response relationships for cAMP production demonstrate reproducible pharmacological profiles across experimental replicates.

Transfected HEK293 cell systems enable controlled receptor expression studies, allowing precise characterisation of binding kinetics and signalling parameters. These heterologous expression systems facilitate structure-function relationship investigations through site-directed mutagenesis approaches.

Enzyme Kinetics and Metabolic Stability

In vitro stability assays using liver microsome preparations demonstrate enhanced metabolic resistance compared to native GHRH. The DAC modification confers protection against enzymatic degradation, measured through LC-MS/MS analysis of compound integrity over time.

Enzymatic binding studies reveal albumin association kinetics, with kon and koff rates determined through surface plasmon resonance. These binding parameters directly influence compound availability for receptor interactions in serum-containing experimental conditions.

Research Summary

CJC-1295 represents a modified GHRH analogue with enhanced pharmacological properties for in vitro research applications. The compound demonstrates selective GHRH-R binding, robust cAMP-PKA pathway activation, and sustained signalling responses in multiple cell model systems. The DAC modification provides unique experimental advantages through albumin binding, enabling extended compound exposure studies. These pharmacological characteristics make CJC-1295 a valuable research tool for investigating growth hormone axis signalling mechanisms in controlled laboratory environments.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.

Hexarelin

TB-500

Epithalon

Ipamorelin

Tirzepatide

CJC-1295 DAC

PT-141

Semaglutide

Selank

BPC-157

Sermorelin

Melanotan 2

IGF LR3

Tesamorelin

AICAR

IGF-DES

GHRP 2

Albuterol

Tamoxifen

Letrozole

Clomiphene

Tadalafil

Clenbuterol

Anastrozole

Finasteride

Exemestane

Sildenafil

Yohimbine

Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows

Already a customer? Sign In

Create Account

All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

Sarms

Stacks

Research Liquids

Albuterol 5MG/ML | 30ML with dropper

Anastrozole 1.5MG/ML | 30ML with dropper

Clomiphene 50MG/ML | 30ML with dropper

Finasteride 5MG/ML | 30ML with dropper

Letrozole 3.5 MG/ML | 30ML with dropper

LiquiCia 30MG/ML | 30ML with dropper

LiquiCia T50 50MG/ML | 30ML with dropper

LiquiClen 200MCG/ML | 30ML with dropper

Liquistane / Exemestane 25MG/ML | 30ML with dropper

LiquiTamo 20MG/ML | 30ML with dropper

LiquiVia 25MG/ML | 30 ML with dropper

T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper

Toremifene Citrate 60MG/ML | 30ML with dropper

Yohimbine HCL 10MG/ML | 30ML with dropper

Research Peptides

Aicar 50MG

BPC-157 + TB-500 Blend 2mg ea/ 4MG

BPC-157 5MG

CJC-1295 + DAC 2MG

CJC-1295 | No DAC 2MG

Epithalon 10MG

Frag Premium 176-191 5MG

GHK-CU Copper Peptide 50MG

GHRP-2 5MG

GHRP-6 5MG

Hexarelin 5MG

IGF-1 DES 1MG

IGF-1 LR3 1MG

Ipamorelin 5MG

Melanotan 2 10MG

NAD+ 500MG

PT-141 / Bremelanotide 10MG

GLP-1/GIP/GCG (RT)

Selank 5MG

GLP1 (SM)

Sermorelin 5MG

TB-500 5MG

GIP/GLP-1 (TZ)

PDE5 Inhibitors

GLP-1

Diluents

Bacteriostatic Water 10ML